{"id":"W4389480683","doi":"10.1016/j.iotech.2023.100693","title":"LBA3 Durvalumab (D) ± tremelimumab (T) + chemotherapy (CT) in first-line (1L) metastatic NSCLC (mNSCLC): 5-year (y) overall survival (OS) update from the POSEIDON study","year":2023,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Medicine; Internal medicine; Durvalumab; Regimen; Chemotherapy; Gastroenterology; Progression-free survival; Nuclear medicine; Confidence interval; Oncology; Immunotherapy; Pembrolizumab; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001612457,0.0006060202,0.00141911,0.0008981072,0.0003158675,0.00003941052,0.001049347,0.0004411705,0.001198363],"category_scores_gemma":[0.0003318563,0.0004645087,0.0003152696,0.002438789,0.0007602196,0.0001310002,0.0003483199,0.001155668,0.000456615],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008040701,"about_ca_system_score_gemma":0.0004852102,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002571119,"about_ca_topic_score_gemma":0.006078797,"domain_scores_codex":[0.995767,0.000464225,0.001207721,0.0009952752,0.0004938462,0.001071913],"domain_scores_gemma":[0.9968348,0.0008267693,0.0003917206,0.001722869,0.0001420187,0.00008184253],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.05302535,0.01150042,0.2505793,0.0001410315,0.01033231,0.006113156,0.006473698,0.000136677,0.1220899,0.001867827,0.02249443,0.5152459],"study_design_scores_gemma":[0.1432552,0.01235464,0.4292913,0.0004586065,0.001171693,0.0006990294,0.01872679,0.0008439933,0.008427606,0.009391535,0.3734807,0.001898869],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9509711,0.003616202,0.00004327789,0.0403178,0.001371529,0.002250215,0.00006944696,0.0008400572,0.0005204048],"genre_scores_gemma":[0.9919168,0.004618244,0.0003033781,0.001692399,0.0001773728,0.0004477862,0.0001884374,0.0001338703,0.0005217447],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.513347,"threshold_uncertainty_score":0.9997807,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02537940517961945,"score_gpt":0.3139009496148696,"score_spread":0.2885215444352501,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}